Список проголосовавших за комментарий " Seres Therapeutics target lowered to $18 at FBR & Co. — Core issues identified support confirming patient diagnosis and optimizing dose (9.89)FBR & Co. lowers their MCRB tgt to $18 from $23 after Seres Therapeutics announced results from its completed in-depth analysis of a Phase II ECOSPOR study with SER-109 in patients with recurrent Clostridium difficile infection (CDI). They think key observations support a potential path forward for SER-109. For example, confirmation of patient diagnosis for CDI using an appropriate assay would optimize the study patient population. They also look for further confirmation of microbiome changes from SER-109 treatment as being meaningful and associated with a decreased rate of CDI recurrence. The in-depth analysis necessitated a delay in SER-109's advancement. However, they conclude that the core issues identified in the analysis favor moving forward with another Phase II study and think high value continues to exist in SER-109; Outperform."